Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT06516965
- Locations
- 🇺🇸
Medical Dermatology Specialists Phoenix, Phoenix, Arizona, United States
🇺🇸Investigate Md, Scottsdale, Arizona, United States
🇺🇸Premier Dermatology Clinical Trials Institute At Northwest Arkansas, Fayetteville, Arkansas, United States
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT06516952
- Locations
- 🇧🇬
Medconsult Pleven, Pleven, Bulgaria
🇵🇱Centrum Medyczne Evimed, Warsaw, Poland
🇺🇸Cahaba Dermatology, Birmingham, Alabama, United States
A Study to Evaluate Skin and Plasma Pharmacokinetic of Multiple Doses of Povorcitinib After Oral Administration in Healthy Participants
- First Posted Date
- 2024-07-17
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT06505265
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States
Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 25
- Registration Number
- NCT06465433
- Locations
- 🇹🇷
Gazi University Hospital Gazi University Faculty of Medicine, Ankara, Turkey
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
🇮🇹Hospital S.M. Terni University of Perugia, Terni, Italy
A Study to Evaluate the Effect of Povorcitinib on the QT/QTc Interval in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-06-04
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 128
- Registration Number
- NCT06441318
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Assess the Effect of Povorcitinib on Digoxin, Rosuvastatin, and Metformin Pharmacokinetics and the Effect of Probenecid on Povorcitinib Pharmacokinetics When Administered Orally to Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-05-16
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 71
- Registration Number
- NCT06416800
- Locations
- 🇺🇸
Fortrea Clinical Research Unit, Dallas, Texas, United States
A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 120
- Registration Number
- NCT06388564
- Locations
- 🇧🇪
Jessa Ziekenhuis, Hasselt, Belgium
🇧🇪Universitair Ziekenhuis (Uz) Leuven, Leuven, Belgium
🇧🇪Az Sint-Jan Brugge - Oostende Av - Campus Sint-Jan, Brugge, Belgium
A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females
- Conditions
- Healthy Participants
- Interventions
- First Posted Date
- 2024-04-23
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06380205
- Locations
- 🇺🇸
Celerion Clinical Research Unit, Tempe, Arizona, United States
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 144
- Registration Number
- NCT06313593
- Locations
- 🇺🇸
University of Pennsylvania Health System, Philadelphia, Pennsylvania, United States
🇺🇸Stanford University, Palo Alto, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Study to Evaluate the Relative Bioavailability of Ruxolitinib Extended Release (XR) Tablets Compared With Ruxolitinib Immediate Release (IR) Tablets Administered Orally in Healthy Participants.
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-06-05
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 24
- Registration Number
- NCT06310304
- Locations
- 🇺🇸
Celerion, Inc, Lincoln, Nebraska, United States